Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current


Connect Biopharma To Announce Long-Term Data From The China Pivotal Trial Of Rademikibart In Patients With Moderate-To-Severe Atopic Dermatitis On November 21, 2023

Author: Benzinga Newsdesk | November 20, 2023 05:42pm

Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will announce topline results from the Stage 2 (maintenance period) of its China pivotal trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) on Tuesday, November 21, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the trial results.


Conference Call and Webcast Presentation

Date and Time: Tuesday, November 21, 2023, at 8:30 a.m. ET

Toll Free: 1-877-407-0784

International: 1-201-689-8560

Conference ID: 13742753

Webcast Presentation: Click Here1

Posted In: CNTB